Carcinoma, Renal CellNeoplasm MetastasisAdultAgedAged, 80 and overMiddle AgedMultivariate AnalysisPrognosisRetrospective StudiesSurvival RateResection of solitary metastases from renal cell carcinoma (RCC) is associated with a 5-year survival rate of 35% to 50%. Selection criteria are not well defined....
The patients were then analyzed related to progression and overall survival (OS). In metastatic clear cell RCC patients, the 1-year OS rate was 69.4% and the median OS was 17.0 months (15.5–18.5) followed up to 203.6 months. When comparing the patient groups, 119 ...
The 5-year survival rate for metastatic RCC is p10%. Recently, microRNAs (miRNAs) have been shown to have a role in cancer metastasis and potential as prognostic biomarkers in cancer. METHOD: We performed a miRNA microarray to identify a miRNA signature characteristic of metastatic compared with...
Grant R, Trevenen C, Hyndman WC, Rubin SZ, Coppes MJ. Metastatic Renal Cell Carcinoma in a child: 11-year disease- free survival following surgery. Med Pediatr Oncol 1997;28: 201-4.Grant R, Trevenen C, Hyndman WC, Rubin SZ, Coppes MJ. Metastatic renal cell carcinoma in a child:...
Interleukin-4 promoter polymorphisms: a genetic prognostic factor for survival in metastatic renal cell carcinoma. PURPOSE: Renal cell carcinoma (RCC) is considered a cytokine-responsive tumor. The clinical course of a patient may thus be influenced by the patient's cap... RE Ramoner,T Kleinrath...
There is a correlation between long-term survival and stage of disease. The 5-year survival rate of stage I RCC is reported to be 66%, and the stage IV survival rate is as low as 11%.7 Surgical resection with cardiopulmonary bypass and deep hypothermal circulatory arrest is the current ...
Patients with metastatic RCC face a dismal prognosis, with a median survival time of only 6 to 12 months and a 2-year survival rate of 10% to 20%. Recent advances in biologic response modifier therapy have brought new hope to a small percentage of patients who respond to this therapy and...
[translate] aSurvival Prediction in Everolimus-treated Patients with Metastatic Renal Cell Carcinoma Incorporating Tumor Burden Response in the RECORD-1 Trial 生存预言在有变形的肾脏细胞癌合并的肿瘤负担反应的Everolimus被对待的病人在RECORD-1试验 [translate] ...
In a randomized phase II trial in metastatic renal cell carcinoma (mRCC), objective response rate was significantly higher with axitinib versus placebo titration (54% vs. 34%; 1-sided P = .019). Patients and Methods Treatment-naive patients with mRCC (n = 213) received axitinib 5 mg twice...
A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma Article Open access 30 September 2022 Vascular heterogeneity of tight junction Claudins guides organotropic metastasis Article 17 September 2024 Molecular characterization of renal cell carcinoma tumors from a phase...